2023
Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis.
Naqvi S, He H, Siddiqi R, Khan N, Khakwani K, Ayaz A, Singh P, Ho T, Bryce A, McGregor B, Xu W, Bin Riaz I. Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis. Journal Of Clinical Oncology 2023, 41: 695-695. DOI: 10.1200/jco.2023.41.6_suppl.695.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMixed treatment comparisonGraphical user interfaceTreatment comparisonsRule-based algorithmSystematic reviewUser interfaceSignificant PFS benefitAdditional survival benefitFirst-line treatmentCertainty of evidenceEfficacious treatment optionRenal cell carcinomaBayesian networkSignificant differencesQuality of lifeAutomated fashionRisk of toxicityEvidence synthesis frameworkImmunotherapy combinationsMRCC patientsOS benefitPFS benefitSynthesis frameworkTreatment toxicityAdjuvant immunotherapy in renal cell carcinoma: A living systematic review and network meta-analysis (NMA).
Sipra Q, Bin Riaz I, Naqvi S, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Singh P, Ho T, Bilen M, Zakharia Y, Bryce A. Adjuvant immunotherapy in renal cell carcinoma: A living systematic review and network meta-analysis (NMA). Journal Of Clinical Oncology 2023, 41: 694-694. DOI: 10.1200/jco.2023.41.6_suppl.694.Peer-Reviewed Original ResearchRenal cell carcinomaDisease-free survivalAdjuvant immunotherapyBaseline riskCell carcinomaTreatment optionsImproved disease-free survivalLocalized Renal Cell CarcinomaRisk categoriesAdjuvant treatment optionsAbsolute risk differenceUnique treatment optionRisk stratification systemMixed treatment comparisonSignificant differencesRelative effect estimatesEvidence synthesis frameworkAdjuvant pembrolizumabNivolumab-ipilimumabOverall survivalTreatment landscapeAbsolute benefitPreferred treatmentRecent trialsDisease progression
2022
Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis
Riaz I, Sipra Q, Naqvi S, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Liu H, Singh P, Ho T, Bilen M, Zakharia Y, Bryce A, Murad M. Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. Critical Reviews In Oncology/Hematology 2022, 175: 103706. PMID: 35537621, DOI: 10.1016/j.critrevonc.2022.103706.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaAbsolute benefitCell carcinomaTreatment-related grade 3Adjuvant treatment optionsHigher adverse eventsDisease-free survivalRisk-adapted strategyDelays disease progressionLarger tumor sizeEvidence synthesis frameworkAdjuvant therapyAdjuvant treatmentOverall survivalAdverse eventsNodal positivityLeibovich scoreTumor sizeTreatment optionsDisease progressionRisk groupsGrade 3Current evidenceComparative effectivenessSystematic review
2021
Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis.
Riaz I, Siddiqi R, Islam M, He H, Riaz A, Asghar N, Naqvi S, Warner J, Murad M, Kohli M. Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis. JCO Clinical Cancer Informatics 2021, 5: 588-599. PMID: 34043431, DOI: 10.1200/cci.21.00035.Peer-Reviewed Original ResearchConceptsAdjuvant tyrosine kinase inhibitorsTyrosine kinase inhibitorsRenal cell carcinomaTrial sequential analysisCell carcinomaTKI monotherapyClinical trialsHigh-risk renal cell carcinomaMultiple large clinical trialsKinase inhibitorsLiving Systematic ReviewRandomized phase 2High-risk patientsCertainty of evidenceLarge clinical trialsKey clinical outcomesAdverse event riskLack of benefitOS benefitPROTECT trialGRADE approachClinical outcomesRandomized trialsCancer recurrenceSTUDY SELECTIONA Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma
Riaz I, He H, Ryu A, Siddiqi R, Naqvi S, Yao Y, Husnain M, Narasimhulu D, Mathew J, Sipra Q, Vandvik P, Joseph R, Liu H, Wang Z, Herasevich V, Singh P, Hussain S, Ho T, Bryce A, Pagliaro L, Murad M, Costello B. A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. European Urology 2021, 80: 712-723. PMID: 33824031, DOI: 10.1016/j.eururo.2021.03.016.Peer-Reviewed Original ResearchConceptsInteractive tableGraphical user interfaceUser interfaceUser-friendly formatAdvanced programmingDisplay resultsInteractive mannerInteractive reviewNetworkSearch strategyCurrent approachesSparse direct evidenceMetastatic renal cell carcinomaData extractionTableFirst-line treatmentProgrammingUntreated metastatic renal cell carcinomaFormatMultiple treatment optionsRenal cell carcinomaInherent biasesAdverse eventsComplete responseFrameworkA framework for living evidence synthesis in cancer: Living, interactive network meta-analysis for first-line treatment of metastatic renal cell carcinoma (mRCC).
Riaz I, He H, Ryu A, Siddiqi R, Naqvi S, Yao Y, Husnain M, Maheswari D, Sipra Q, Montori V, Joseph R, Liu H, Wang Z, Herasevich V, Singh P, Ho T, Bryce A, Pagliaro L, Murad M, Costello B. A framework for living evidence synthesis in cancer: Living, interactive network meta-analysis for first-line treatment of metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2021, 39: 335-335. DOI: 10.1200/jco.2021.39.6_suppl.335.Peer-Reviewed Original ResearchInteractive tableArtificial intelligenceJavaScript programming languageFive-layered architectureMetastatic renal cell carcinomaFirst-line metastatic renal cell carcinomaLine Metastatic Renal Cell CarcinomaProgramming languageProgression-free survivalDifferent teamsComplete responseOverall survivalSystematic reviewSearch strategyDynamic featuresNetworkEvidence synthesisInteractive networkFirst-line treatmentEvidence mapRenal cell carcinomaFrameworkShared-decision makingOverall responseBaseline characteristics